Abstract
Cathelicidin is a host defense peptide with multiple innate immunity-related functions. Recent findings indicate that cathelicidin is frequently dysregulated in human cancers where it plays a paradoxical yet dominant role in the regulation of tumor malignancy. In this review, the regulation of malignant phenotypes by cathelicidin in relation to the activation of its receptors and intracellular signaling is discussed.
Keywords: Angiogenesis, apoptosis, LL-37, receptor, signaling.
Current Medicinal Chemistry
Title:The Janus Face of Cathelicidin in Tumorigenesis
Volume: 21 Issue: 21
Author(s): W.K.K. Wu, J.J.Y. Sung, A.S.L. Cheng, F.K.L. Chan, S.S.M. Ng, K.F. To, X.J. Wang, L. Zhang, S.H. Wong, J. Yu and C.H. Cho
Affiliation:
Keywords: Angiogenesis, apoptosis, LL-37, receptor, signaling.
Abstract: Cathelicidin is a host defense peptide with multiple innate immunity-related functions. Recent findings indicate that cathelicidin is frequently dysregulated in human cancers where it plays a paradoxical yet dominant role in the regulation of tumor malignancy. In this review, the regulation of malignant phenotypes by cathelicidin in relation to the activation of its receptors and intracellular signaling is discussed.
Export Options
About this article
Cite this article as:
Wu W.K.K., Sung J.J.Y., Cheng A.S.L., Chan F.K.L., Ng S.S.M., To K.F., Wang X.J., Zhang L., Wong S.H., Yu J. and Cho C.H., The Janus Face of Cathelicidin in Tumorigenesis, Current Medicinal Chemistry 2014; 21 (21) . https://dx.doi.org/10.2174/0929867321666140205135351
DOI https://dx.doi.org/10.2174/0929867321666140205135351 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protective and Therapeutic Effects of Ghrelin in the Gut
Current Medicinal Chemistry Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases
Current Clinical Pharmacology Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective
Current Pharmaceutical Design Regulation and Function of Rankl in Arterial Calcification
Current Pharmaceutical Design Curcumin Reverts the Protein Differential Expression in the Liver of the Diabetic Obese db/db Mice
Current Proteomics Endoplasmic Reticulum Stress and Atherosclerosis
Current Hypertension Reviews Polysaccharide-Based Nanobiomaterials as Controlled Release Systems for Tissue Engineering Applications
Current Pharmaceutical Design PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update
Current Vascular Pharmacology Stent Thrombosis and Duration of Dual Antiplatelet Therapy
Current Pharmaceutical Design Endothelin Receptor Antagonists: Another Potential Alternative for Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders Formaldehyde as a trigger for protein aggregation and potential target for mitigation of age-related, progressive cognitive impairment
Current Topics in Medicinal Chemistry Adrenomedullin as a Potential Therapeutic Agent for Inflammatory Bowel Disease
Current Protein & Peptide Science Endothelial Dysfunction in the Hypertensive State: Mechanisms of Hypertensive Cardiovascular Complications
Current Hypertension Reviews Attenuation of Microvascular Injury in Preconditioned Ischemic Myocardium: Imaging with Tc-99m Glucaric Acid and In-111 Human Fibrinogen
Current Molecular Imaging (Discontinued) Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Current Pharmaceutical Design Sphingolipid Signaling and Hematopoietic Malignancies: To the Rheostat and Beyond
Anti-Cancer Agents in Medicinal Chemistry Adjunctive Therapy for Percutaneous Revascularization in Acute Myocardial Infarction
Current Pharmaceutical Design PI-3 Kinase-PTEN Signaling Node: An Intercept Point for the Control of Angiogenesis
Current Pharmaceutical Design Infection-Associated Biomarkers of Inflammation in Atherosclerosis
Current Pharmaceutical Design Modulation of Fatty Acids Oxidation in Heart Failure by Selective Pharmacological Inhibition of 3-Ketoacyl Coenzyme-A Thiolase
Current Clinical Pharmacology